Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02843438

Acronym

BIOLUVE

Enrollment

Registered

2016-07-25

Start date

2010-01-31

Completion date

2016-01-31

Last updated

2016-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjects Clinically Suspected an Active Source of Toxoplasmosis Chorioretinitis Infection

Keywords

Toxoplasmosis, Uveitis, Chorioretinitis, Infection

Brief summary

Toxoplasmosis affects one to two newborn each 10000 births. Among them, 1 to 2 % develop learning disabilities or die, and 4 to 27 % develop a chorioretinitis sometimes leading to an amblyopia responsible for visual impairment. Toxoplasmosis uveitis affects too adults immunocompetent and immunodepressed who have had an acquired toxoplasmosis. Clinical diagnosis of ocular toxoplasmosis is more complicated in presence of posterior neuro-retinitis, inflammation of the papilla, uveitis without chorioretinitis, fuchs heterochromic iridocyclitis, scleritis, diffuse necrotizing or multifocal retinitis. In this situation biological markers diagnostic and prognostic of toxoplasmosis uveitis are useful. Highly kept molecules (during evolution) like stress proteins (Hsp) are are found in the host and the pathogen and there can trigger a crossed immune response. Stress proteins haven't been explored yet, in the context of toxoplasmosis uveitis on humans. The hypothesis is that Hsp70 and antibodies anti-Hsp70 are diagnostic and prognostic markers of ocular toxoplasmosis. The goal is to evaluate diagnosis value of biological markers (Hsp70 and antibodies IgG anti-Hsp70) in toxoplasmosis uveitis.

Interventions

OTHERFluorescein angiography

OTHERDilated fundus examination

BIOLOGICALToxoplasmosis serology

DRUGAnti-toxoplasmosis treatment

DRUGAnti-inflammatory treatments

OTHERPuncture in anterior chamber

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Age

No minimum to 18 Years

Healthy volunteers

Inclusion criteria

* Age over 18 years * Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection * Persons affiliated to national social security

Exclusion criteria

* Pregnant, parturient or breastfeeding women * Persons deprived of liberty by judicial or administrative decision, person under legal protection * Refusal by a patient to do the PCA (anterior chamber puncture) * Patients whose following will be difficult or nonexistent

Design outcomes

Primary

Measure	Time frame	Description
ELISA tests	About an hour	ELISA (enzyme linked immunosorbent assay) tests. Biological markers evaluation : stress protein Hsp70 and antibodies anti-Hsp70.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026